MiniMed Group, Inc. (MMED)
Nasdaq · Healthcare · Medical Instruments & Supplies
$20.16+2.34%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $5.7B
- Forward P/E
- 31.6
- 52-week range
- $10.65 – $24.43
- 52-week change
- +6.54%
- EPS (trailing)
- −$1.53
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 16, 2026
Fiscal year to Apr 2026
- Revenue
- $3.1B (+14.25%)
- Net income
- −$333M
- Operating margin
- −6.1%
- Diluted EPS
- −$1.30
- Free cash flow
- −$420M
From the company’s annual report on SEC EDGAR.
About MiniMed Group, Inc.
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services. It also offers CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California. MiniMed Group, Inc. operates as a subsidiary of Medtronic plc.
Headquarters: Northridge, United States · 8,000 employees · minimed.com